Key result
Point-of-care D-dimer testing for suspected DVT saves ~€103 per patient vs lab testing with similar outcomes.
Why the study?
The cost-effectiveness of point-of-care-test D-dimer assays compared to regular laboratory-based assays in the diagnostic work-up of DVT was unknown.
Does a point-of-care D-dimer testing strategy improve cost-effectiveness compared to laboratory-based testing for excluding DVT in general practice?
Does a point-of-care D-dimer testing strategy improve cost-effectiveness compared to laboratory-based testing for excluding DVT in general practice?
Answers are grounded in this paper and cite their sources.
Point-of-care D-dimer testing for DVT exclusion in primary care is cost-saving and yields similar health outcomes compared to standard laboratory testing.
BACKGROUND: In the diagnostic work-up of deep vein thrombosis (DVT), the use of point-of-care-test (POCT) D-dimer assays is emerging as a promising patient-friendly alternative to regular D-dimer assays, but their cost-effectiveness is unknown. We compared the cost-effectiveness of two POCT-based approaches to the most common, laboratory-based, situation. METHODS: A patient-level simulation model was developed to simulate the diagnostic trajectory of patients presenting with symptoms of DVT at the general practitioner (GP). Three strategies were defined for further diagnostic work-up: one based on current guidelines ('regular strategy') and two alternative approaches where a POCT for D-dimer is implemented at the 1) phlebotomy service ('DVT care pathway') and 2) GP practice ('fast-POCT strategy'). Probabilities, costs and health outcomes were obtained from the literature. Costs and effects were determined from a societal perspective over a time horizon of 6 months. Uncertainty in model outcomes was assessed with a one-way sensitivity analysis. RESULTS: The Quality-Adjusted Life Years (QALYs) scores for the three DVT diagnostic work-up strategies were all around 0.43 across a 6 month-time horizon. Cost-savings of the two POCT-based strategies compared to the regular strategy were €103/patient for the DVT care pathway (95% CI: -€117-89), and €87/patient for the fast-POCT strategy (95% CI: -€113-67). CONCLUSIONS: Point-of-care-based approaches result in similar health outcomes compared with regular strategy. Given their expected cost-savings and patient-friendly nature, we recommend implementing a D-dimer POCT device in the diagnostic DVT work-up.
No takes yet. Share an insight, caveat, or question.
Heerink et al. (2023) studied Suspected deep vein thrombosis (n=10,000). Point-of-care D-dimer testing (DVT care pathway) vs. Regular strategy (laboratory-based D-dimer assay) was evaluated on Cost-savings per patient (€103 cost-savings, 95% CI -117 to 89). Point-of-care D-dimer testing for suspected deep vein thrombosis yielded similar health outcomes but saved €87 to €103 per patient compared to the regular laboratory-based strategy.
Synapse has enriched 10 related papers. Consider them for comparative context: